Avalyn Pharma (AVLN)
Develops inhaled pirfenidone and nintedanib candidates for pulmonary fibrosis.
$36.02
Pre-market+0.55 (+1.55%)
At close$35.47(+0.54%)
Something off on this page? Send us feedback.
EPSReportedEstimate
——————Jun '26Aug '26
Reported——————−$21.83−$0.98
Estimate——————−$5.98−$0.78
Surprise——————−265.3%−26.2%
RevenueReportedEstimate
——————Jun '26Aug '26
Reported————————
Estimate————————
Surprise————————
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Aug 2026 | −$0.78 | −$0.98 | −26.2% |
| Jun 2026 | −$5.98 | −$21.83 | −265.3% |
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Aug 12, 2026 | −$0.78 | −$0.98 | −26.2% | — | — | — | +5.4% |
| Jun 3, 2026 | −$5.98 | −$21.83 | −265.3% | — | — | — | +2.2% |